SVB Failure Could Exacerbate Tight Credit, Drive Biopharma Consolidation
Executive Summary
An economist told Scrip that banks could become more cautious about handing out loans to biotech start-ups, driving more M&A in the sector.
You may also be interested in...
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Year Ahead Could Prove Rough For Private Biotech Financing
The second half of 2022 saw a downturn in fundraising by venture capital firms, and panelists at BIO CEO said that could spell trouble in 2023.
Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases
The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.